OneDigital Investment Advisors LLC Makes New $460,000 Investment in Natera, Inc. $NTRA

OneDigital Investment Advisors LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,696 shares of the medical research company’s stock, valued at approximately $460,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Integrated Wealth Concepts LLC lifted its position in Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth increased its holdings in Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Natera in the 2nd quarter valued at about $298,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Natera in the 2nd quarter valued at about $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NTRA. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price on the stock. BTIG Research boosted their target price on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Natera in a research report on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $319.38.

Natera Price Performance

Natera stock opened at $325.07 on Thursday. The company has a market cap of $46.86 billion, a price-to-earnings ratio of -239.02 and a beta of 1.51. The firm has a 50-day moving average of $269.73 and a 200-day moving average of $228.01. Natera, Inc. has a one year low of $156.71 and a one year high of $326.03.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the previous year, the business earned ($0.74) earnings per share. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Transactions at Natera

In other news, Director Herm Rosenman sold 16,530 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This represents a 79.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.